Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(29%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
14%
Ph not_applicable
2
29%
Ph phase_1
4
57%

Phase Distribution

4

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
4(57.1%)
Phase 2Efficacy & side effects
1(14.3%)
N/ANon-phased studies
2(28.6%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

7

all time

Status Distribution
Active(2)
Completed(2)
Other(3)

Detailed Status

unknown3
Recruiting2
Completed2

Development Timeline

Analytics

Development Status

Total Trials
7
Active
2
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (57.1%)
Phase 21 (14.3%)
N/A2 (28.6%)

Trials by Status

recruiting229%
completed229%
unknown343%

Recent Activity

2 active trials
Showing 5 of 7
recruitingphase_1

68Ga-P16-093 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI

NCT07209865
recruitingnot_applicable

68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients

NCT05324332
completedphase_1

Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer

NCT03073395
unknownphase_1

68Ga-P16-093 PET/CT Imaging in the Salivary Gland

NCT06049368
completednot_applicable

68Ga-P16-093 and 18F-FDG PET/CT Imaging in the Same Group of Clear Cell Renal Cell Carcinoma Patients

NCT05432947
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07209865Phase 1

68Ga-P16-093 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI

Recruiting
NCT05324332Not Applicable

68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients

Recruiting
NCT03073395Phase 1

Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer

Completed
NCT06049368Phase 1

68Ga-P16-093 PET/CT Imaging in the Salivary Gland

Unknown
NCT05432947Not Applicable

68Ga-P16-093 and 18F-FDG PET/CT Imaging in the Same Group of Clear Cell Renal Cell Carcinoma Patients

Completed
NCT05569434Phase 1

68Ga-P16-093 PET/CT Imaging in Glioma Patients

Unknown
NCT04796467Phase 2

68Ga-P16-093 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients

Unknown

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7